help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chuang, T. T.
Right arrow Articles by Enjalbert, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chuang, T. T.
Right arrow Articles by Enjalbert, A.

Endocrinology, Vol 132, 832-838, Copyright © 1993 by Endocrine Society


ARTICLES

Protein kinase C regulation of prolactin gene expression in lactotroph cells: involvement in dopamine inhibition

TT Chuang, L Caccavelli, C Kordon and A Enjalbert
Unite 159, INSERM, Paris, France.

The role of protein kinase C (PKC) on dopamine inhibition of PRL messenger RNA (mRNA) levels was studied in anterior pituitary cells kept in primary culture. PKC was desensitized by long-term exposure to 12-O-tetradecanoylphorbol 13-acetate (TPA). Effectiveness of PKC desensitization was confirmed by the fact that after TPA pretreatment, short-term (1-h) exposure to TPA was no longer able to trigger PRL release. In contrast, the capacity of nonreceptor-mediated secretagogues as depolarization with 48 mM K+ to release the hormone was preserved. Pretreatment with TPA did not affect basal PRL mRNA levels. In contrast, it significantly reduced the dose-dependent inhibition of PRL mRNA induced by 1 nM bromocriptine after a 4-day incubation period. Since dopamine inhibition of PRL release is mediated by several second messager pathways, including cAMP, inositol phosphates, and Ca2+, we investigated whether PKC depletion was able to interact with direct stimulation of these pathways. Pretreatment with PKC suppressed stimulation of PRL mRNA levels induced by either Forskolin (FK) or 8Br-cAMP. In parallel, it reduced basal as well as FK stimulated intracellular cAMP levels. In addition, chronic exposure to TPA completely suppressed PRL mRNA inhibition induced by nifedipine, a dihydropyridine antagonist which blocks voltage-dependent Ca2+ channels. TPA desensitization also affected the action of bromocriptine, FK or nifedipine on PRL release measured under the same conditions. The data indicate that endogenous PKC can interfere with the regulation of PRL gene expression induced by both cAMP and Ca2+ pathways, two second messengers associated with the action of dopamine in lactotroph cells.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Ishida, T. Mitsui, K. Yamakawa, N. Sugiyama, W. Takahashi, H. Shimura, T. Endo, T. Kobayashi, and J. Arita
Involvement of cAMP response element-binding protein in the regulation of cell proliferation and the prolactin promoter of lactotrophs in primary culture
Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1529 - E1537.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. Ben-Jonathan and R. Hnasko
Dopamine as a Prolactin (PRL) Inhibitor
Endocr. Rev., December 1, 2001; 22(6): 724 - 763.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Hus-Citharel, N. Bouby, J. Marchetti, D. Chansel, D. Goidin, D. Gourdji, P. Corvol, and C. Llorens-Cortes
Desensitization of Type 1 Angiotensin II Receptor Subtypes in the Rat Kidney
Endocrinology, November 1, 2001; 142(11): 4683 - 4692.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C.-C. Chuang, S.-K. Tan, L.-K. Tai, J.-P. Hsin, and F.-F. Wang
Evidence for the Involvement of Protein Kinase C in the Inhibition of Prolactin Gene Expression by Transforming Growth Factor-beta 2
Mol. Pharmacol., June 1, 1998; 53(6): 1054 - 1061.
[Abstract] [Full Text]


Home page
J. Histochem. Cytochem.Home page
A. Matsuno, S. Takekoshi, N. Sanno, H. Utsunomiya, Y. Ohsugi, N. Saito, H. Kanemitsu, A. Tamura, T. Nagashima, R. Y. Osamura, et al.
Modulation of Protein Kinases and Microtubule-associated Proteins and Changes in Ultrastructure in Female Rat Pituitary Cells: Effects of Estrogen and Bromocriptine
J. Histochem. Cytochem., January 1, 1997; 45(6): 805 - 814.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society